Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 21, 2019; 25(31): 4405-4413
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4405
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4405
Size | IAP (Fukuoka) 2012 | IAP (Fukuoka) 2017 | ACG 2018 | ACR 2018 | European 2018 | AGA 2015 |
< 1 cm | CT/MRI in 2-3 yr | CT/MRI in 6 mo then every 2 yr | MRI q 2 yr (lengthen after4) | MRI/CT q1 year for cysts < 1.5 cm and q6 mo for cysts 1.5-2.5 cm × 4 and then lengthen interval; stop after stability over 10 yr1 | Surveillance q 6 mo × 2 with MRI and/or EUS, CA19-9; if stable lifelong surveillance is recommended with annual MRI/EUS, CA19-9 | MRI in 1 yr, then every 2 for 5 yr Stop if stable |
1-2 cm | CT/MRI annually × 2 yr, then lengthen interval if stable | CT/MRI in 6 m × 1 yr A Annually × 2 yr, then lengthen interval if stable | MRI q 1 yrs FOR 3 yr Then q 2 yr FOR 4 yr | |||
2-3 cm | EUS in 3-6 mo, then lengthen interval, alternate MRI with EUS as appropriate | EUS in 3-6 mo, then lengthen interval, alternate MRI with EUS as appropriate | EUS/MRI q 6mo for 3 yr then yearly for 4 yr | For cysts > 2.5 cm q6 mo MRI/CT and then stop if stable for over 10 yr; for patients > 80 yr of age, q2 year imaging1 | ||
> 3 cm | Alternate MRI/EUS every 3-6 mo | Alternate MRI/EUS every 3-6 mo | EUS/MRI q 6mo for 3 yr then yearly for 4 yr |
- Citation: Hasan A, Visrodia K, Farrell JJ, Gonda TA. Overview and comparison of guidelines for management of pancreatic cystic neoplasms. World J Gastroenterol 2019; 25(31): 4405-4413
- URL: https://www.wjgnet.com/1007-9327/full/v25/i31/4405.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i31.4405